Hepatitis Research Today is a free monthly online journal that collates and summarizes the latest research about Hepatitis, including details on hepatitis a, b, c, causes, symptoms.

Volume 2 (2007), Issue 5 (May)

1. Individual and couple-level risk factors for hepatitis C infection among heterosexual drug users: a multilevel dyadic analysis.
   J Infect Dis, 195(11): 1572-81. [Abstract] [Full-text]
2. Impact of hepatitis B virus basic core promoter mutations on T cell response to an immunodominant HBx-derived epitope.
   Hepatology, 45(5): 1199-209. [Abstract] [Full-text]
3. HBsAg seroclearance in asymptomatic carriers of high endemic areas: appreciably high rates during a long-term follow-up.
   Hepatology, 45(5): 1187-92. [Abstract] [Full-text]
4. Serum HBV RNA is a predictor of early emergence of the YMDD mutant in patients treated with lamivudine.
   Hepatology, 45(5): 1179-86. [Abstract] [Full-text]
5. Cognitive function does not worsen during pegylated interferon and ribavirin retreatment of chronic hepatitis C.
   Hepatology, 45(5): 1154-63. [Abstract] [Full-text]
6. Hepatitis B viral factors in HBeAg-negative carriers with persistently normal serum alanine aminotransferase levels.
   Hepatology, 45(5): 1193-8. [Abstract] [Full-text]
7. Twenty-four-week clevudine therapy showed potent and sustained antiviral activity in HBeAg-positive chronic hepatitis B.
   Hepatology, 45(5): 1172-8. [Abstract] [Full-text]
8. Liver stiffness measurement predicts severe portal hypertension in patients with HCV-related cirrhosis.
   Hepatology, 45(5): 1290-7. [Abstract] [Full-text]
9. Terbinafine-induced acute autoimmune hepatitis in the setting of hepatitis B virus infection.
   Ann Pharmacother, 41(5): 880-4. [Abstract] [Full-text]
10. Clinical and virological characteristics of hepatitis B virus subgenotypes Ba, C1, and C2 in China.
    J Clin Microbiol, 45(5): 1491-6. [Abstract] [Full-text]
11. Anger experiences among hepatitis C patients: relationship to depressive symptoms and health-related quality of life.
    Psychosomatics, 48(3): 223-9. [Abstract] [Full-text]
12. Telbivudine: a new option for the treatment of chronic hepatitis B.
    Expert Opin Biol Ther, 7(5): 751-61. [Abstract] [Full-text]
13. Human immunodeficiency virus and hepatitis C virus testing services at syringe exchange programs: availability and outcomes.
    J Subst Abuse Treat, 32(4): 423-9. [Abstract] [Full-text]
14. Integrating hepatitis prevention services into a substance use disorder clinic.
    J Subst Abuse Treat, 32(4): 391-8. [Abstract] [Full-text]
15. Infection of human hepatocyte chimeric mouse with genetically engineered hepatitis C virus and its susceptibility to interferon.
    FEBS Lett, 581(10): 1983-7. [Abstract] [Full-text]
16. Use of serological assays for diagnosis of hepatitis E virus genotype 1 and 3 infections in a setting of low endemicity.
    Clin Vaccine Immunol, 14(5): 562-8. [Abstract] [Full-text]
17. Hepatitis B virus infection.
    Semin Fetal Neonatal Med, 12(3): 160-7. [Abstract] [Full-text]
18. Hepatitis C virus infection.
    Semin Fetal Neonatal Med, 12(3): 168-73. [Abstract] [Full-text]
19. The hepatitis C virus epidemic in Cameroon: genetic evidence for rapid transmission between 1920 and 1960.
    Infect Genet Evol, 7(3): 361-7. [Abstract] [Full-text]
20. Hepatitis E virus.
    Rev Med Virol, 17(3): 151-80. [Abstract] [Full-text]
21. Hepatitis E virus infection in work horses in Egypt.
    Infect Genet Evol, 7(3): 368-73. [Abstract] [Full-text]
22. Adefovir dipivoxil treatment of lamivudine-resistant chronic hepatitis B.
    Antiviral Res, 75(2): 146-51. [Abstract] [Full-text]
23. Human monoclonal antibody against Hepatitis B virus surface antigen (HBsAg).
    Antiviral Res, 75(2): 113-20. [Abstract] [Full-text]
24. The hepatitis C virus life cycle as a target for new antiviral therapies.
    Gastroenterology, 132(5): 1979-98. [Abstract] [Full-text]
25. Inhibition of T-cell inflammatory cytokines, hepatocyte NF-kappaB signaling, and HCV infection by standardized Silymarin.
    Gastroenterology, 132(5): 1925-36. [Abstract] [Full-text]
26. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir.
    Gastroenterology, 132(5): 1767-77. [Abstract] [Full-text]
27. Mutation rate of the hepatitis C virus NS5B in patients undergoing treatment with ribavirin monotherapy.
    Gastroenterology, 132(5): 1757-66. [Abstract] [Full-text]
28. Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study.
    Gastroenterology, 132(5): 1746-56. [Abstract] [Full-text]
29. Immunogenicity of candidate hepatitis E virus DNA vaccine expressing complete and truncated ORF2 in mice.
    Vaccine, 25(22): 4350-60. [Abstract] [Full-text]
30. Suppression of immune-mediated liver injury after vaccination with attenuated pathogenic cells.
    Immunol Lett, 110(1): 29-35. [Abstract] [Full-text]
31. Herb-induced hepatitis by Teucrium polium L.: report of two cases and review of the literature.
    Eur J Gastroenterol Hepatol, 19(6): 507-11. [Abstract] [Full-text]
32. Chronic hepatitis C infection and sicca syndrome: a clear association with HLA DQB1*02.
    Eur J Gastroenterol Hepatol, 19(6): 493-8. [Abstract] [Full-text]
33. Risk of non-Hodgkin lymphoma and lymphoproliferative precursor diseases in US veterans with hepatitis C virus.
    JAMA, 297(18): 2010-7. [Abstract] [Full-text]
34. Serum globulin levels in predicting the extent of hepatic fibrosis in patients with recurrent post-transplant hepatitis C infection.
    Clin Transplant, 21(3): 391-7. [Abstract] [Full-text]
35. Remission in autoimmune hepatitis: what is it, and can it ever be achieved?
    Am J Gastroenterol, 102(5): 1013-5. [Abstract] [Full-text]
36. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: a hospital-based case-control study.
    Am J Gastroenterol, 102(5): 1016-21. [Abstract] [Full-text]
37. Improving the end point of corticosteroid therapy in type 1 autoimmune hepatitis to reduce the frequency of relapse.
    Am J Gastroenterol, 102(5): 1005-12. [Abstract] [Full-text]
38. Compartmentalization of hepatitis C virus (HCV) during HCV/HIV coinfection.
    J Infect Dis, 195(12): 1765-73. [Abstract] [Full-text]
39. Monocyte-derived dendritic cell function in chronic hepatitis C is impaired at physiological numbers of dendritic cells.
    Clin Exp Immunol, 148(3): 494-500. [Abstract] [Full-text]
40. No direct hepatotoxic potential following a multiple-low dose paraquat exposure in rat as related to its bioaccumulation.
    Toxicol Lett, 170(3): 193-202. [Abstract] [Full-text]
41. Poly(I:C) and lipopolysaccharide innate sensing functions of circulating human myeloid dendritic cells are affected in vivo in hepatitis C virus-infected patients.
    J Virol, 81(11): 5537-46. [Abstract] [Full-text]
42. Human serum amyloid A protein inhibits hepatitis C virus entry into cells.
    J Virol, 81(11): 6128-33. [Abstract] [Full-text]
43. Prevalence and genotyping of hepatitis E virus in swine population in Korea between 1995 and 2004: a retrospective study.
    Vet J, 173(3): 683-7. [Abstract] [Full-text]
44. Awareness of hepatitis C diagnosis is associated with less alcohol use among persons co-infected with HIV.
    J Gen Intern Med, 22(6): 822-5. [Abstract] [Full-text]
45. MRP2 haplotypes confer differential susceptibility to toxic liver injury.
    Pharmacogenet Genomics, 17(6): 403-15. [Abstract] [Full-text]
46. Evaluation of human (genotype 1) and swine (genotype 4)-ORF2-based ELISAs for anti-HEV IgM and IgG detection in an endemic country and search for type 4 human HEV infections.
    J Viral Hepat, 14(6): 435-45. [Abstract] [Full-text]
47. Distribution and characteristics of hepatitis B virus genotype C subgenotypes in China.
    J Viral Hepat, 14(6): 426-34. [Abstract] [Full-text]
48. No significant differences in histology and response to interferon treatment in hepatitis B carriers of genotypes C and recombinant B.
    J Viral Hepat, 14(6): 419-25. [Abstract] [Full-text]
49. High incidence of hepatitis C virus reinfection within a cohort of injecting drug users.
    J Viral Hepat, 14(6): 413-8. [Abstract] [Full-text]
50. Impaired ability of interferon-alpha-primed dendritic cells to stimulate Th1-type CD4 T-cell response in chronic hepatitis C virus infection.
    J Viral Hepat, 14(6): 404-12. [Abstract] [Full-text]
51. Pharmacokinetics and enhanced PKR response in patients with chronic hepatitis C treated with pegylated interferon alpha-2b and ribavirin.
    J Viral Hepat, 14(6): 396-403. [Abstract] [Full-text]
52. Clearance of hepatitis C virus in HIV-infected patients with multiple chronic viral hepatitis.
    J Viral Hepat, 14(6): 392-5. [Abstract] [Full-text]
53. Critical role of ribavirin for the achievement of early virological response to HCV therapy in HCV/HIV-coinfected patients.
    J Viral Hepat, 14(6): 387-91. [Abstract] [Full-text]
54. Therapeutic issues in HIV/HCV-coinfected patients.
    J Viral Hepat, 14(6): 371-86. [Abstract] [Full-text]
55. Immunomodulation as an option for the treatment of chronic hepatitis B virus infection: preclinical studies in the woodchuck model.
    Expert Opin Investig Drugs, 16(6): 787-801. [Abstract] [Full-text]
56. Treatment paradigms on hepatitis B e antigen-negative chronic hepatitis B patients.
    Expert Opin Investig Drugs, 16(6): 777-86. [Abstract] [Full-text]
57. The APRI may be enhanced by the use of the FIBROSpect II in the estimation of fibrosis in chronic hepatitis C.
    Clin Chim Acta, 381(2): 119-23. [Abstract] [Full-text]
58. Biochemical and virologic parameters in patients co-infected with hepatitis C and HIV versus patients with hepatitis C mono-infection.
    Am J Med Sci, 333(5): 271-5. [Abstract] [Full-text]
59. Severe intimal hyperplasia with ischaemic colitis in two patients with hepatitis C.
    Intern Med J, 37(5): 326-9. [Abstract] [Full-text]
60. Peroxisome proliferator-activated receptor alpha protects against obesity-induced hepatic inflammation.
    Endocrinology, 148(6): 2753-63. [Abstract] [Full-text]
61. Desflurane hepatitis associated with hapten and autoantigen-specific IgG4 antibodies.
    Anesth Analg, 104(6): 1452-3, table of contents. [Abstract] [Full-text]
62. Hepatoprotective role of endogenous interleukin-13 in a murine model of acetaminophen-induced liver disease.
    Chem Res Toxicol, 20(5): 734-44. [Abstract] [Full-text]
63. Impact of peginterferon alpha-2b and ribavirin treatment on liver tissue in patients with HCV or HCV-HIV co-infection.
    J Infect, 54(6): 609-16. [Abstract] [Full-text]
64. Hepatitis B genotypes and response to antiviral therapy: a review.
    Am J Ther, 14(3): 306-9. [Abstract] [Full-text]
65. Immunization with hepatitis C virus-like particles results in control of hepatitis C virus infection in chimpanzees.
    Proc Natl Acad Sci U S A, 104(20): 8427-32. [Abstract] [Full-text]
66. Fibrin ring granuloma in chronic hepatitis C: virus-related vasculitis and/or immune complex disease?
    Semin Liver Dis, 27(2): 227-30. [Abstract] [Full-text]
67. Guidelines for therapy of autoimmune liver disease.
    Semin Liver Dis, 27(2): 214-26. [Abstract] [Full-text]
68. Interpreting serological tests in diagnosing autoimmune liver diseases.
    Semin Liver Dis, 27(2): 161-72. [Abstract] [Full-text]
69. Chronic infections with hepatotropic viruses: mechanisms of impairment of cellular immune responses.
    Semin Liver Dis, 27(2): 152-60. [Abstract] [Full-text]
70. The impact of autoimmunity on hepatocytes.
    Semin Liver Dis, 27(2): 140-51. [Abstract] [Full-text]
71. Role of lamivudine in the posttransplant prophylaxis of chronic hepatitis B virus and hepatitis delta virus coinfection.
    Transplantation, 83(10): 1341-4. [Abstract] [Full-text]
72. Should hepatitis B vaccination be introduced into childhood immunisation programmes in northern Europe?
    Lancet Infect Dis, 7(6): 410-9. [Abstract] [Full-text]
73. Clinical implications of HIV and hepatitis B co-infection in Asia and Africa.
    Lancet Infect Dis, 7(6): 402-9. [Abstract] [Full-text]
74. Trends in post-liver transplant survival in patients with hepatitis C between 1991 and 2001 in the United States.
    Liver Transpl, 13(5): 719-24. [Abstract] [Full-text]
75. Hepatitis C recurrence and fibrosis progression are not increased after living donor liver transplantation: a single-center study of 289 patients.
    Liver Transpl, 13(5): 687-92. [Abstract] [Full-text]
76. Liver transplantation for HCV cirrhosis: improved survival in recent years and increased severity of recurrent disease in female recipients: results of a long term retrospective study.
    Liver Transpl, 13(5): 733-40. [Abstract] [Full-text]
77. Prevalence of risk factors for hepatitis C virus in HIV-infected and HIV/hepatitis C virus-coinfected patients.
    Sex Transm Dis, 34(6): 367-70. [Abstract] [Full-text]
78. B safe, B sorted: results of a hepatitis B vaccination outreach programme.
    Int J STD AIDS, 18(5): 335-7. [Abstract] [Full-text]
79. Enhancement of gene transactivation activity of androgen receptor by hepatitis B virus X protein.
    Virology, 363(2): 454-61. [Abstract] [Full-text]
80. The impact of chronic hepatitis C on health-related quality of life in homeless and marginally housed individuals with HIV.
    AIDS Behav, 11(4): 603-10. [Abstract] [Full-text]
81. Hepatitis C viremia increases the association with type 2 diabetes mellitus in a hepatitis B and C endemic area: an epidemiological link with virological implication.
    Am J Gastroenterol, 102(6): 1237-43. [Abstract] [Full-text]
82. Efficacy of lamivudine therapy in elderly patients with chronic hepatitis B infection.
    J Gastroenterol, 42(5): 395-401. [Abstract] [Full-text]
83. A randomized trial of induction doses of interferon alone or in combination with ribavirin or ribavirin plus amantadine for treatment of nonresponder patients with chronic hepatitis C.
    J Gastroenterol, 42(5): 362-7. [Abstract] [Full-text]
84. Drug resistance in antiviral treatment for infections with hepatitis B and C viruses.
    J Gastroenterol, 42(5): 329-35. [Abstract] [Full-text]
85. Prevalence of and factors associated with hepatic steatosis in patients coinfected with hepatitis C virus and HIV: Agence Nationale pour la Recherche contre le SIDA et les hépatites virales CO3 Aquitaine Cohort.
    J Acquir Immune Defic Syndr, 45(2): 168-73. [Abstract] [Full-text]
86. External quality assessment for the molecular detection of Hepatitis C virus.
    J Clin Virol, 39(2): 141-4. [Abstract] [Full-text]
87. Determination of hepatitis B virus genotype by flow-through reverse dot blot.
    J Clin Virol, 39(2): 94-100. [Abstract] [Full-text]
88. Liver enzyme flares and occult hepatitis B in persons with chronic hepatitis C infection.
    J Clin Virol, 39(2): 101-5. [Abstract] [Full-text]
89. Hepatitis B virus (HBV) genotypes/subgenotypes in China: mutations in core promoter and precore/core and their clinical implications.
    J Clin Virol, 39(2): 87-93. [Abstract] [Full-text]
90. Hepatitis C virus (HCV) coinfection in a cohort of HIV positive long-term non-progressors: possible protective effect of infecting HCV genotype on HIV disease progression.
    J Clin Virol, 39(2): 82-6. [Abstract] [Full-text]
91. Progression of fibrosis during chronic hepatitis C is associated with rapid virus evolution.
    J Virol, 81(12): 6513-22. [Abstract] [Full-text]
92. Overlap of autoimmune hepatitis and primary biliary cirrhosis: long-term outcomes.
    Am J Gastroenterol, 102(6): 1244-50. [Abstract] [Full-text]
93. Immunotherapy for severe aplastic anemia following orthotopic liver transplantation in children.
    Pediatr Blood Cancer, 49(1): 93-8. [Abstract] [Full-text]
94. Modeling the mechanisms of acute hepatitis B virus infection.
    J Theor Biol, 247(1): 23-35. [Abstract] [Full-text]
95. Reconstruction of the hepatitis C virus epidemic in the US hemophilia population, 1940-1990.
    Am J Epidemiol, 165(12): 1443-53. [Abstract] [Full-text]

© 2006-2008 Hepatitis Research Today. All Rights Reserved.